Colinz Laboratories Complete Financial Statements
In FY2026, Colinz Laboratories (COLINZ) reported revenue ₹6 Cr, net profit ₹1 Cr and EPS ₹2.04, with a net profit margin of 16.7% and ROE of 10.0%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review Colinz Laboratories price earnings to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
COLINZ Revenue, Net Profit & EBITDA — Year-on-Year Growth
COLINZ YoY (March 2025 vs March 2026) — revenue -14.3%, EBITDA -100.0%. For live price, earnings ratios and company overview, see COLINZ share price screener.
COLINZ Income Statement — Revenue, EBITDA & Net Profit
Colinz Laboratories revenue ₹6 Cr, EBITDA ₹0 Cr, net profit ₹1 Cr, EPS ₹2.04 (2026) — net profit margin 16.7%. Explore COLINZ Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 7 | 7 | 7 | 7 | 6 | 8 | 8 | 8 | 8 | 8 | 8 |
| Expenses | 6 | 6 | 7 | 7 | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 7 |
| EBITDA | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit Margin % | 7.00% | 8.00% | 8.00% | 9.00% | 8.00% | 5.00% | 4.00% | 5.00% | 5.00% | 5.00% | 6.00% | 6.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 2.04 | 1.97 | 1.93 | 1.82 | 0.74 | 0.45 | -0.01 | 0.34 | 0.65 | 0.40 | 0.21 | 0.21 |
COLINZ Balance Sheet — Assets, Liabilities & Shareholders' Equity
COLINZ total assets ₹13 Cr, total equity ₹10 Cr, total liabilities ₹ Cr (2026) — ROE 10.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 13 | 12 | 11 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 11 |
| Current Assets | 10 | 9 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 6 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 0 | 9 | 9 | 8 | 7 | 8 | 6 | 7 | 7 | 7 | 7 | 8 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 3 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 10 | 10 | 9 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 6 | 6 |
| Share Capital | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 8 | 7 | 6 | 6 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
COLINZ Cash Flow Statement — Operating, Investing & Financing
Colinz Laboratories operating cash flow ₹-2 Cr, investing ₹0 Cr, financing ₹0 Cr, net cash flow ₹-2 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Net Cash Flow | -2 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 1 |